

## Special Issue

# Emerging Trends in Liver Diseases and Cirrhosis Research

### Message from the Guest Editor

Liver diseases remain a growing global health challenge, with cirrhosis being one of the leading causes of morbidity and mortality worldwide. The clinical landscape is rapidly changing, driven by the rising prevalence of metabolic-associated steatotic liver disease (MASLD), autoimmune conditions like primary biliary cholangitis (PBC), and persistent viral hepatitis. At the same time, advances in diagnostic tools, molecular understanding, and therapeutic strategies are providing new hope for earlier intervention and better outcomes. This Special Issue provides an opportunity to highlight recent advancements and emerging frontiers in hepatology research.

We aim to gather cutting-edge research and comprehensive reviews focusing on new developments in the diagnosis, pathophysiology, and management of cirrhosis. Special attention will be given to innovations in the diagnosis and treatment of MASLD, PBC, and other chronic liver conditions. The collection aligns with the journal's commitment to publishing high-quality research that advances clinical and scientific understanding of complex disease processes.

### Guest Editor

Dr. Hariklia Kranidioti

2nd Academic Department of Internal Medicine, General Hospital of Athens "Hippokratio", Medical School of National and Kapodistrian University of Athens, Athens, Greece

### Deadline for manuscript submissions

31 March 2026



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/247528](https://mdpi.com/si/247528)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).